Venadaparib is under clinical development by Idience and currently in Phase I for Gastric Cancer. According to GlobalData, Phase I drugs for Gastric Cancer have a 77% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Venadaparib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
IDX-1197 (NOV1401) is under development for the treatment of solid tumors including high-grade serious ovarian cancer, breast cancer, gastroesophageal junction, gastric cancer and pancreatic cancer. It is formulated as capsule and administered orally. It acts by targeting PARP-1 and PARP-2.
It was under development for the treatment of prostate cancer, endometrial cancer, fallopian tube cancer and uterine cancer.
Idience, a subsidiary of Ildong Pharmaceutical Co Ltd, is a biopharmaceutical company engaged in research, development and marketing of novel drugs for the treatment of cancer disease. The company is headquartered in Seoul City, Seoul, South Korea.
For a complete picture of Venadaparib’s drug-specific PTSR and LoA scores, buy the report here.